quinoxalines has been researched along with plx4032 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gallagher, SJ; Gowrishankar, K; Gunatilake, D; Hersey, P; Rizos, H; Tiffen, J | 1 |
| Annan, RS; Bamborough, P; Bush, JT; Chung, CW; Dixon, DP; Fallon, DJ; Fantom, KGM; Grant, EK; Hann, MM; House, D; Patel, VK; Quinn, C; Stacey, P; Tomkinson, NCO; Zappacosta, F | 1 |
2 other study(ies) available for quinoxalines and plx4032
| Article | Year |
|---|---|
Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.
Topics: B7-H1 Antigen; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Indoles; Interferon-gamma; Melanoma; NF-kappa B; Quinoxalines; Sulfonamides; Time Factors; Vemurafenib | 2015 |
A Photoaffinity-Based Fragment-Screening Platform for Efficient Identification of Protein Ligands.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cross-Linking Reagents; Humans; Ligands; Molecular Structure; Photoaffinity Labels; Proteins; Pyrazoles; Quinoxalines; Sulfonamides; Vemurafenib | 2020 |